"Tetrazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D013777
|
| MeSH Number(s) |
D03.383.129.617
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tetrazoles".
Below are MeSH descriptors whose meaning is more specific than "Tetrazoles".
This graph shows the total number of publications written about "Tetrazoles" by people in this website by year, and whether "Tetrazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 3 | 3 |
| 1997 | 2 | 2 | 4 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 2 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 4 | 1 | 5 |
| 2005 | 2 | 0 | 2 |
| 2006 | 3 | 1 | 4 |
| 2007 | 2 | 1 | 3 |
| 2008 | 2 | 2 | 4 |
| 2009 | 2 | 0 | 2 |
| 2010 | 2 | 2 | 4 |
| 2011 | 3 | 2 | 5 |
| 2012 | 5 | 0 | 5 |
| 2013 | 2 | 1 | 3 |
| 2014 | 9 | 3 | 12 |
| 2015 | 9 | 0 | 9 |
| 2016 | 13 | 1 | 14 |
| 2017 | 8 | 2 | 10 |
| 2018 | 4 | 6 | 10 |
| 2019 | 9 | 2 | 11 |
| 2020 | 6 | 3 | 9 |
| 2021 | 0 | 5 | 5 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tetrazoles" by people in Profiles.
-
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial. Circ Heart Fail. 2023 03; 16(3):e010111.
-
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2022 09 20; 80(12):1130-1143.
-
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovasc Diabetol. 2022 06 18; 21(1):110.
-
Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF. JACC Heart Fail. 2022 06; 10(6):415-427.
-
Atrial Fibrillation in Heart?Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2022 05; 10(5):336-346.
-
Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. Eur J Heart Fail. 2022 03; 24(3):551-561.
-
Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. Eur J Heart Fail. 2022 09; 24(9):1591-1598.
-
Long-term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program. Epilepsia. 2022 01; 63(1):139-149.
-
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021 09 21; 42(36):3741-3752.
-
Integrating High-Sensitivity Troponin T and?Sacubitril/Valsartan Treatment in?HFpEF: The PARAGON-HF Trial. JACC Heart Fail. 2021 09; 9(9):627-635.